Suspended supply of new cholesterol-lowering drug Evolocumab? Sanofi responds

Market news shows that several hospitals have recently received official notifications from Sanofi: the new lipid-lowering drug Praluent will cease its promotion in the Chinese market and gradually withdraw from the Chinese market, with a deadline of July 2025. In response, Sanofi stated, "Sanofi's decision to discontinue the supply of Praluent in the Chinese market is mainly due to global supply issues, as well as the company's cardiovascular market strategy and pipeline optimization. The company acquired the exclusive development and commercialization rights for aficamten in the Greater China region from JiStar at the end of 2024, and recently announced the acquisition of the rights for the in-development drug Pulzirolan Sodium Injection from Viazenn in the Greater China region. The company's cardiovascular product strategy in China will undergo a comprehensive upgrade to continue providing innovative products from different fields to meet the needs of domestic patients."